|
|
 |
Program of the conference:
|
|
Monday, Sept 13, 2010
|
|
13.00 h
|
Welcome
|
Prof. Dr. A. Buschauer
|
|
13.10-14.10 h
|
Carbohydrates – using the “undruggable” for diagnostics and vaccines
|
Prof. Dr. Peter Seeberger,
Max-Planck-Institut für Kolloid- und Grenzflächen- forschung, Potsdam, D
|
|
14.10-15.10 h
|
Structure of G protein-coupled receptors (GPCRs): Implications for ligand binding and activation
|
Prof. Dr. Gebhard F. X. Schertler,
Paul Scherrer Institute, Villigen, CH
|
|
Coffee break
|
|
|
|
15.40-16.40 h
|
Fragment based discovery of H4 receptor antagonists
|
Prof. Dr. Rob Leurs,
VU University Amsterdam, NL
|
|
16.40-17.40 h
|
Tailor-made GPCR ligands as molecular probes
|
Prof. Dr. Peter Gmeiner,
University of Erlangen, D
|
| Coffee break |
|
|
| 18.00-19.00 h |
Synthesis and evaluation of phenanthropiperidine alkaloids for anticancer activity and CNS side effects |
Prof. Dr. Gunda I. Georg,
University of Minnesota, MN, USA |
| 19.00-19.30 h |
Oral poster presentation |
|
| 19.30 h |
Poster session / Beer and bretzel |
|
|
|
Tuesday, Sept 14, 2010
|
| 8.30-9.30 h |
Eicosanoids and cancer-chemoprevention: cox, lox and beyond |
Prof. Dr. Stefan Laufer,
University of Tübingen, D |
| 9.30-10.30 h |
Target identfication, hit discovery and lead optimization in the field of endocrinology and intracrinology |
Prof. Dr. Rolf W. Hartmann,
Saarland University, Saarbrücken, D |
| Coffee break |
|
|
| 11.00-12.00 h |
A case study: From research to market - Xarelto, a new anti-thrombotic principle |
Prof. Dr. Martin Schneider,
Bayer Schering Pharma AG, Berlin, D |
| 12.00-12.30 h |
Oral poster presentation |
|
| Lunch break |
|
|
| 13.45-14.45 h |
Fragment-based lead discovery: Different perspectives |
Dr. Gerhard Hessler,
Sanofi-Aventis Deutschland GmbH, Frankfurt/M., D |
| 14.45-15.45 h |
ANCHOR SEARCH: Web-based tool for the design of protein protein interaction antagonists |
Prof. Dr. Alexander Dömling,
University of Pittsburgh, PA, USA |
| 15.45-16.00 h |
Oral poster presentation |
|
| Coffee break |
|
|
| 16.30-17.30 h |
Quantum-chemical computation of compound properties, bioisosterism and protein ligand interactions |
Dr. Michael Thormann,
Origenis GmbH, Martinsried, D |
| 17.30-18.30 h |
Challenges in agrochemicals design |
Prof. Dr. Klaus-Jürgen Schleifer,
BASF SE, Ludwigshafen, D |
| 18.30-18.45 h |
Oral poster presentation |
|
| 18.45-20.00 h |
Poster session |
|
| 20.00 h |
Barbecue at the University of Regensburg |
|
|
|
Wednesday, Sept 15, 2010
|
| 8.30-9.45 h |
A holistic look at developability of new chemical entities |
Dr. Ralph Lipp,
Lilly Research Laboratories, Indianapolis, IN, USA |
| 9.45-10.45 h |
Gender: The forgotten aspect in drug development |
Prof. Dr. Oliver Werz,
University of Tübingen, D |
| Coffee break |
|
|
| 11.15-12.15 h |
Drugs for orphan diseases |
Prof. Dr. Roland Seifert,
Medical School of Hannover, D |
| 12.15-13.15 h |
ADME problems? Rescue your candidate |
Prof. Dr. Hugo Kubinyi,
University of Heidelberg, D |
| 13.15 h |
Concluding remarks |
|
|
|
